Vyzulta

Chemical Namelatanoprostene bunod ophthalmic solution
Dosage FormSolution (topical ophthalmic; 0.24 mg/mL (0.024%))
Drug ClassOphthalmic agents
SystemOcular
CompanyBausch & Lomb
Approval Year2017

Indication

  • Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?